Envestnet Asset Management Inc. Increases Stock Holdings in Cytokinetics, Incorporated $CYTK

Envestnet Asset Management Inc. increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 100.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 59,068 shares of the biopharmaceutical company’s stock after acquiring an additional 29,601 shares during the period. Envestnet Asset Management Inc.’s holdings in Cytokinetics were worth $3,246,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CYTK. EverSource Wealth Advisors LLC raised its stake in shares of Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Cytokinetics by 68.4% in the third quarter. Farther Finance Advisors LLC now owns 1,115 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 453 shares during the period. Hantz Financial Services Inc. grew its holdings in Cytokinetics by 2,872.7% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,264 shares in the last quarter. Root Financial Partners LLC purchased a new stake in Cytokinetics during the 3rd quarter worth $80,000. Finally, GAMMA Investing LLC increased its stake in Cytokinetics by 109.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,472 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 769 shares during the period.

Insider Buying and Selling

In other news, Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. The trade was a 38.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John T. Henderson sold 8,750 shares of the stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $63.90, for a total transaction of $559,125.00. Following the sale, the director owned 74,578 shares in the company, valued at approximately $4,765,534.20. This trade represents a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 151,385 shares of company stock worth $9,817,158. Company insiders own 3.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CYTK. Morgan Stanley set a $90.00 price objective on shares of Cytokinetics in a research report on Thursday, January 8th. HC Wainwright increased their price target on Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a report on Monday, December 22nd. The Goldman Sachs Group set a $95.00 price objective on Cytokinetics and gave the company a “buy” rating in a research note on Thursday, December 18th. Barclays started coverage on Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 target price on the stock. Finally, Wall Street Zen cut Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Sixteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $88.28.

Cytokinetics Stock Up 2.7%

NASDAQ:CYTK opened at $70.10 on Wednesday. The company has a market cap of $8.57 billion, a PE ratio of -11.14 and a beta of 0.54. The business’s 50 day moving average is $64.14 and its two-hundred day moving average is $58.32. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.26) earnings per share. As a group, sell-side analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Regulatory approvals and commercial launch — MYQORZO® received approval for adults with symptomatic obstructive HCM in the U.S., China and Europe, and the U.S. launch is underway with first prescriptions already dispensed, supporting potential near‑term revenue growth. GlobeNewswire Release
• Positive Sentiment: Upcoming clinical catalyst — the company expects to report topline results from the ACACIA‑HCM study in Q2 2026, a binary event that could materially affect valuation depending on outcomes. GlobeNewswire Release
• Positive Sentiment: Strong balance sheet and guidance — management provided 2026 guidance and reported roughly $1.2 billion in cash, cash equivalents and investments as of year‑end 2025, reducing near‑term financing risk. GlobeNewswire Release
• Positive Sentiment: Analyst optimism — at least one outlet raised CYTK’s price target (to $101), signaling bullish analyst views that likely supported buying interest. Price Target Note
• Neutral Sentiment: Quarterly transcript and business update available — management discussed results and the commercial plan on the Q4 2025 call; investors can review the full transcript and press release for details on launch execution and guidance. Earnings Transcript
• Neutral Sentiment: Revenue growth — Q4 revenue rose ~4.9% year‑over‑year and beat consensus revenue expectations, offering some validation of early commercial traction and R&D monetization. Zacks Report
• Negative Sentiment: EPS miss and widening loss — GAAP EPS was a ($1.50) loss versus the ($1.48) consensus and a larger loss than a year ago, underscoring ongoing profitability pressure as the company scales commercialization. Zacks Report
• Negative Sentiment: Analyst views mixed — some coverage notes divergent analyst opinions on commercial ramp and valuation, which can add volatility until clearer revenue trends or clinical readouts emerge. Globe and Mail Coverage

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.